MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ...

The FDA approved an inhaled needle-free insulin and a Delaware County teenager was part of the four year clinical trial.

U.S. Food and Drug Administration (FDA) has approved Afrezza Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes.

On Friday, the FDA expanded its approved use for kids 6 years and older who have Type 1 diabetes or those who require insulin ...

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they manage school, sports, meals, and snacks ...

On Friday, the FDA expanded its approved use of Afrezza — making it the first ever needle-free insulin option for pediatric ...

New analyses examine Afrezza across pediatric A1c and efficacy, patient treatment satisfaction, use with AID algorithms and investigator-led ...

The FDA has approved technosphere insulin, an inhaled form of human insulin, for children and adolescents aged 6 years and ...

MannKind CFO Matthew Pfeffer still believes that inhaled insulin Afrezza will be a blockbuster therapy despite a lackluster product launch. “There are a lot of problems with current insulin therapies, ...

When Sanofi announced it was returning the marketing rights for inhaled insulin Afrezza in January, doubts were cast on the future of MannKind Corp, the maker of the drug. Since then, the key question ...

If MannKind (NASDAQ:MNKD) could say Afrezza reduces complications such as hypoglycemic events, weight gain, premature organ failure, etc., Afrezza would be one of the most successful product launches ...

Afrezza (insulin human) is a brand-name medication that’s prescribed for diabetes. The cost of the drug, with and without insurance, can depend on several factors, such as whether Afrezza has a ...